Real World Studies, LA-SER Research

First published: 23/03/2012

Last updated: 23/03/2012







Institution identification

Institution ID	
2484	
Institution countries	
France	
United Kingdom	
Type of institution	
Other	
Institution website	
https://www.LA-SER.com	
ENCePP partner	

Institution description

Yes

LA-SER was founded in 2004, with a mission to bring cutting-edge scientific methodology to evaluate the real-world impact of medicines. Our goal is to find for whom and under which conditions of use the drugs will demonstrate best benefit to patients, with minimal harm. For that purpose, we champion observational and pragmatic studies, with an enviable track record of success. We are pioneers in pharmacoepidemiology and populational health impact assessment of medicines. We also use decision analysis, pharmacoeconomics and Other strategy consulting skills to analyse issues and target drugs at their best. LA-SER has a team of over 150 Late-phase Specialists to work alongside the main actors in the medicines world such as drug and devices manufacturers, regulators, payers and interest groups. LA-SER has recently acquired Analytica International, BAP Health and PBE consulting. As a result, LA-SER is now operating with both active consulting and operational teams in 12 countries.

Institution details

Experience with collecting data directly from individual patients or respondents:

Yes

Interest in carrying out research that is funded by pharmaceutical companies:

Yes

Contact

Hayley Chaplin Hayley. Chaplin@la-ser.com



Hayley.Chaplin@la-ser.com

Lamiae Grimaldi lamiae.grimaldi@la-ser.com

Alternate

lamiae.grimaldi@la-ser.com